Yong-Sung Kim
Dr. Yong-Sung Kim has been a professor in the Department of Molecular Science and Technology at Ajou University (Suwon, Korea) since 2004. He currently serves as the Dean of the newly established College of Advanced Bio-Convergence Engineering at Ajou University. Dr. Kim earned his Ph.D. in Pharmaceutical Sciences from the University of Colorado, USA, in 2002. He completed a postdoctoral fellowship in the laboratory of Prof. K. Dane Wittrup at MIT and spent his sabbatical year (2010–2011) at Genentech, Inc. (San Francisco, USA). Dr. Kim’s research focuses on the development of therapeutic antibody platform technologies, including heterodimeric Fc-based bispecific antibodies, immunocytokines, and cytosol-penetrating antibodies. He has published over 120 peer-reviewed articles and filed or obtained more than 100 domestic and international patents. Dr. Kim was a scientific co-founder of Orum Therapeutics Inc. (2016) and Pinetree Therapeutics Inc. (Boston, USA, 2019). Additionally, he has transferred over five antibody-related technologies to companies in Korea and the United States. His website is http://antibody.ajou.ac.kr/.
Abstracts this author is presenting: